Fosamprenavir plus Ritonavir Increases Plasma Ketoconazole and Ritonavir Exposure, while Amprenavir Exposure Remains Unchanged

Plasma ketoconazole (KETO), amprenavir (APV), and ritonavir (RTV) pharmacokinetics were evaluated in 15 healthy subjects after being treated with KETO at 200 mg once daily (QD), fosamprenavir (FPV)/RTV at 700/100 mg twice daily (BID), and then KETO at 200 mg QD plus FPV/RTV at 700/100 mg BID in this...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Wire, Mary B., Ballow, Charles H., Borland, Julie, Shelton, Mark J., Lou, Yu, Yuen, Geoffrey, Lin, Jiang, Lewis, Eric W.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology 2007
Assuntos:
Antiviral Agents
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC1932497/
https://ncbi.nlm.nih.gov/pubmed/17517848
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00008-07
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados